


Salazopyrin ad infinitum!



“It is concluded that maintenance treatment of ulcerative colitis with sulphasalazine (salazopyrin) should be continued indefinitely unless contraindicated by side effects.”¹

The results of the above controlled trial carried out at the Nuffield Department of Clinical Medicine, Radcliffe Infirmary, Oxford are all the more welcome as earlier trials of cortisone² and prednisone³ at standard dosages have shown them to be ineffective in reducing the number of recurrences of ulcerative colitis.


“Fortunately, Sulphasalazine tablets, 0.5 grams 4 times a day will prevent relapses in the majority

of patients with colitis, and only a few patients cannot tolerate this relatively small dose, which can be continued indefinitely since we do not know when, if ever, it can be safely stopped”.⁴

Salazopyrin (sulphasazine) is available as the plain 0.5g. tablet, 0.5g. EN-tab and as an 0.5g. suppository.

Literature and detailed information on Salazopyrin are available on request.

“The patients who received dummy tablets had more than four times the relapse rate of those receiving sulphasalazine”.¹ (Salazopyrin).



Both groups of patients had been satisfactorily maintained for 1-5 years on Salazopyrin prior to the study, in which they took Salazopyrin or placebo for 6 months.

1. Gut (1973) 14 923 - 926
2. Brit. med. J. (1959) 1 387 - 394
3. Lancet (1965) 1 188 - 189
4. General Practitioner (1972) April 7 p11

Salazopyrin is a registered trade mark.

Further information on request from:-
Pharmacia (Great Britain) Ltd.
Paramount House,
75 Uxbridge Road,
London W5 5SS.
Telephone: 01-579 0102/7



**AN IMPORTANT
ANNOUNCEMENT FROM
MAY & BAKER:

A MAJOR,
NEW INDICATION
FOR 'FLAGYL'**

the treatment and prevention of anaerobic infections

Modern methods reveal the size of the problem

Sophisticated laboratory techniques now show the true incidence of anaerobic infections. Increasingly, these organisms are isolated from clinical specimens,¹ and are implicated in a wide variety of infections.¹⁻³

'FLAGYL' is the dependable answer

Free from the problems associated with other agents in this field (eg chloramphenicol) and, unlike penicillin, active against both sporing and non-sporing forms - 'Flagyl' is bactericidal to most of the clinically important, obligatory anaerobes.¹ 'Flagyl' has been used successfully in the following conditions: pelvic,⁴ intra-abdominal⁵ and post-operative⁴ infections, brain abscess⁶ septic thrombophlebitis⁷ and necrotizing pneumonia.⁸

Positive benefits to the hospital unit

"... it may be concluded that the prophylactic use of metronidazole ('Flagyl') in the test group resulted in a saving to the N.H.S. of almost £2,000 ... prevention of anaerobic infection enabled the gynaecological ward to handle an additional 26 major surgical cases each year."⁴

Backed by an unrivalled reputation

'Flagyl' has an outstanding record of efficacy and safety in over 15 years of clinical experience. It is now firmly established in the treatment of urogenital trichomoniasis, amoebiasis, giardiasis and acute ulcerative gingivitis.

References

1. *Drug and Therapeutic Bulletin*, 14, 25, 1976
2. Phillips, I. and Sussman, M. p.37 *Infections with Non-Sporing Anaerobes* Published Churchill
3. Study group. *Lancet*, ii, 1540, 1974
4. Study group. *J. Antimicrobial Chemotherapy*, 1, 393-401, 1975
5. Willis, A.T., et al., *Br.Med.J.*, February 7, 1, 318-321, 1976
6. Ingham, H.R., et al., *Br.Med.J.*, iv, 39, 1975
7. Mitre, R.J. & Rotheram, E.B., *J.Amer.Med.Assoc.*, 230, 1168, 1974
8. Tally, F.P., et al., *Antimicrobial Agents & Chemotherapy*, 7, 672, 1975

'Flagyl' is supplied as tablets of 200 mg and tablets of 400 mg. Full prescribing information on request
*trade mark of May & Baker Ltd Dagenham Essex
RM10 7XS for its preparations of metronidazole.



M&B May & Baker




A member of the Rhône-Poulenc Group of Companies


In haemorrhoids Fybogel complements topical therapy, by raising the level of natural fibre in the diet.

Fybogel produces softer, well-formed stools. And that reduces straining—a principal cause of haemorrhoids. By complementing topical therapy Fybogel helps to provide a complete treatment for haemorrhoids.

Strain remover



The new Fujinon Endoscopes



Pyser Limited are pleased to introduce the Fujinon range of flexible endoscopes for Upper and Lower Gastrointestinal Tract.

The small diameter forward viewing Oesophago Gastro Duodenoscope has four way tip control and can be angled to 180°. It also has twin light channels and Biopsy facilities.

Duodenoscopy and Cannulation are catered for with the 1360mm length Duodenoscope.

For the Colonoscopist there is a choice of three lengths, 1130mm, 1360mm and 1855mm all of 13mm diameter and having forcep control. All Colonoscopes are insulated for use with Diathermy.

The Fujinon range has been designed in co-operation with practising Endoscopists throughout the world and many of the irritating problems which occur in fibrescopes have been eliminated.

Air, water and suction are controlled by electronic micro-switches for simple trouble-free operation, powered by the low cost light source.

Automatic photography is available with a choice of 8mm cine or 35mm still from the Fuji camera range utilising the standard light source.

Fuji, one of the world's leading optical companies, have been producing fibre bundles for many years and the image quality of the Fujinon fibrescopes is unsurpassed.

Send for literature or a hospital demonstration — Fujinon fibrescopes have many other special features worth your attention — and are backed with after sales service by Pyser Ltd., a company with more than 50 years experience in the optical and scientific industry.

An important advance in Endoscope design

FUJINON

Sole UK Distributor: Pyser Ltd., Edenbridge, Kent

For full information please contact:

Pyser Ltd., Endoscopy Division, 102 College Road, Harrow, Middlesex HA1 1BQ. Tel: 01-427 2278

Digestion

International Journal of Gastroenterology

Contents Vol. 13, No. 6, 1975

Original Papers


- Böhmer, R. and Rommel, K.* (Ulm): Effect of Secretin on Intestinal Mono-saccharide Absorption and Net Water Movement in the Rat... 325
- Balanzo, J. T. and Glass, G. B. J.* (New York, N.Y.): Bioassay of Inhibitory Activity of Gastrone on Basal HCl Secretion in Rats with Chronic Gastric Fistula..... 334

Recent Advances

- Douglas, A. P. and Weetman, A. P.* (Newcastle upon Tyne): Lymphocytes and the Gut..... 344

Short Communications

- Pointner, H.* (Vienna): Normal Serum Gastrin Levels in Patients with Liver Cirrhosis..... 372
- Obituary. Claude V. Perrier..... 375
- Author Index..... 376
- Subject Index..... 380
- Contents Vol. 13..... after 386



S. Karger
 Basel · München
 Paris · London
 New York · Sydney

Please complete the attached order form and return it to:
 S. Karger AG, Arnold-Böcklin-Strasse 25,
 CH-4011 Basel (Switzerland)

- Please enter my subscription
 Please send me a specimen copy

Name _____

Address _____